Introduction
Cephalosporins are suitable for the antimicrobial treatment of osteomyelitis and septic arthritis because they can be given in high doses for prolonged periods with relatively little toxicity.
A limiting factor in the use of the older cephalosporins was a lack of activity against Pseudomonas aeruginosa, an organism which may often superinfect chronic bony lesions or surgical prostheses.
Ceftazidime has a broad spectrum of antibacterial activity, including Ps. aeruginosa (Harper, Kirby & O'Callaghan, 1980) , and favourable human phannacokinetics (Harding et al., 1981) . Wittman et al. (1981) have reported high bone concentrations after 2 g of ceftazidime intravenously. We were therefore interested in evaluating the clinical efficacy and tolerance of ceftazidime in patients with acute and chronic osteomyelitis.
Materials and methods
Patients of both sexes were eligible for inclusion if clinical and microbiological evidence of osteomyelitis was present. Those with a history of cephalosporin allergy or with a 229 0305/7453/83/12A229+05 J02.00/0history of antibiotic use in the preceding two days, pregnant women and patients with a creatinine clearance below 10 ml/min were excluded. Patients were also excluded if the isolated bacteria were not sensitive to ceftazidime or if a possible adverse reaction occurred during treatment. A thorough physical examination was performed before, during and at the completion of a course of therapy.
A complete blood count, chemistry profile and urinalysis were performed before the initiation of therapy, 2 to 5 days after starting therapy, regularly during the remainder of the treatment period, and 1 to 3 days afterwards. Appropriate bacteriological specimens were taken during the 48 h prior to entry into the study. Further specimens for microbiological examination were taken 2 to 5 days after onset of therapy, regularly during the remainder of the treatment period and 24 to 48 h after its end.
Pathogens were tested for sensitivity to ceftazidime, gentamicin, penicillin, cefamandole, carbenicillin and ampicillin by a disc method; MICs of ceftazidime were determined.
Ceftazidime was administered by intravenous infusion (subclavian) over a period of 10 min in the majority of patients. Ten patients received 2 g iv three times daily initially; in four of them the dose was reduced to 1 g iv three times daily when the organism was eradicated. Eleven patients were treated with 1 g iv three times daily throughout.
The assessment of microbiological results were made according to the following guidelines.
Success. Initial pathogen eliminated as shown by post-treatment tests. Superinfection. Eradication of pre-treatment pathogen but superinfection with one or more different pathogens.
Relapse. Initial pathogen eliminated by treatment but recurring during follow-up. Failure. Initial pathogen not eliminated by the therapy. The clinical response was considered as an improvement if the clinical findings subsided significantly in a reasonable period of time but with incomplete resolution of evidence of infection.
Verbal informed consent was obtained from all the patients.
Results
Twenty-one patients (18 males, 3 females) entered the study and were evaluable (Tables  I and II) . Mean age was 43-2 (range 20 to 76) years. The severity of the infection was mild in one case, moderate in 11 and severe in nine cases. The organisms isolated are in Tables  I and II. The bacteriological results showed initial eradication of the organism in every instance. However, in two cases (one Ps. aeruginosa and one Staph. aureus) the same organism was isolated within 14 days after stopping treatment Colonization with Ps. maltopohilia occurred in two cases, but it was without clinical significance since the organism disappeared without any treatment
The average duration of therapy was 33 days (range 9 to 56 days). Fifteen out of 21 patients also had surgical treatment including drainage, debridement and sequestrectomy.
All seven of the cases of acute osteomyelitis were cured and no relapse occurred during follow-up periods ranging from 1 month to 15 months (mean 6 months).
Eleven of 14 with chronic osteomyelitis were cured, one improved and two were considered as failures since relapse occurred with the same organism within 14 days after stopping treatment. No further relapse occurred in any of those patients during a follow-up period ranging from 3 to 16 months (mean 11-9 months). Tolerance was excellent and no side-effect was reported. Haematological and biochemical results showed no abnormality except a transient elevation in liver enzymes in two patients and a positive Coombs test during treatment in six patients which subsided on follow-up.
The Coombs test became positive only after treatment for more than one month and only in those patients who received 6 g ceftazidime daily for periods ranging from 31 to 56 days.
Discussion
Ceftazidime has been shown to penetrate well into bone in the few instances studied (Wittman et al., 1981) . Our study confirms that ceftazidime is effective in patients with acute or chronic osteomyelitis since our overall results show an 85% (18/21) cure rate both bacteriologically and clinically. Adequate drainage and debridement also played a role in the favourable clinical response.
Although ceftazidime has only moderate activity in vitro against Staph. aureus, five out of the six cases were cured clinically and the organism eradicated without relapse during a follow-up period of up to 16 months.
Ceftazidime seems to have no toxic effects, which is important in the treatment of osteomyelitis since therapy lasts for approximately 4 to 6 weeks in most of the cases.
On the basis of these results, we consider ceftazidime to be an effective and safe antibiotic in the treatment of osteomyelitis due to sensitive organisms, especially Gram-negative rods, including multiply-resistant Pseudomonas spp.
